-
EP3936130
European procedure
Extract from the Register of European Patents
EP About this file: EP3936130
| EP3936130 - VALBENAZINE DOSAGE REGIMEN FOR THE TREATMENT OF HYPERKINETIC MOVEMENT DISORDERS [Right-click to bookmark this link] | |||
| Former [2022/02] | VALBENAZINE DOSAGE REGIMEN THE TREATMENT OF HYPERKINETIC MOVEMENT DISORDERS | ||
| [2023/38] | Status | The patent has been granted Status updated on 12.01.2024 Database last updated on 02.09.2024 | |
| Former | Grant of patent is intended Status updated on 03.09.2023 | ||
| Former | Request for examination was made Status updated on 14.10.2022 | ||
| Former | The application has been published Status updated on 10.12.2021 | Most recent event Tooltip | 16.02.2024 | Change - divisional application(s) | published on 20.03.2024 [2024/12] | Applicant(s) | For all designated states Neurocrine Biosciences, Inc. 12780 El Camino Real San Diego, California 92130 / US | [2022/02] | Inventor(s) | 01 /
O'BRIEN, Christopher San Diego, 92130 / US | [2022/02] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [2022/02] | Application number, filing date | 21178882.3 | 06.05.2015 | [2022/02] | Priority number, date | US201461989240P | 06.05.2014 Original published format: US 201461989240 P | [2022/02] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3936130 | Date: | 12.01.2022 | Language: | EN | [2022/02] | Type: | B1 Patent specification | No.: | EP3936130 | Date: | 14.02.2024 | Language: | EN | [2024/07] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 22.11.2021 | Classification | IPC: | A61K31/473, A61P25/00, A61P25/14, A61P43/00 | [2022/02] | CPC: |
A61K31/473 (EP,CN,IL,RU,US);
A61K31/4745 (IL,KR,US);
A61K9/0019 (IL);
A61K9/0053 (IL);
A61K9/08 (IL);
A61K9/20 (IL);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/46] |
| Former [2022/02] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | DOSIERUNGSSCHEMA FÜR VALBENAZIN ZUR BEHANDLUNG VON HYPERKINETISCHEN BEWEGUNGSSTÖRUNGEN | [2022/02] | English: | VALBENAZINE DOSAGE REGIMEN FOR THE TREATMENT OF HYPERKINETIC MOVEMENT DISORDERS | [2023/38] | French: | RÉGIME POSOLOGIQUE DE VALBÉNAZINE POUR LE TRAITEMENT DES TROUBLES DE MOUVEMENT HYPERKINÉTIQUE | [2022/02] |
| Former [2022/02] | VALBENAZINE DOSAGE REGIMEN THE TREATMENT OF HYPERKINETIC MOVEMENT DISORDERS | Examination procedure | 03.08.2022 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time | 12.10.2022 | Amendment by applicant (claims and/or description) | 12.10.2022 | Examination requested [2022/46] | 12.10.2022 | Date on which the examining division has become responsible | 04.09.2023 | Communication of intention to grant the patent | 08.01.2024 | Fee for grant paid | 08.01.2024 | Fee for publishing/printing paid | 08.01.2024 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP15724438.5 / EP3139925 | Divisional application(s) | EP24157482.1 | Request for further processing for: | The application is deemed to be withdrawn due to non-payment of designation fees SK, MT, MK, MC, LV, LU, LT, IT, IS, IE, HU, HR, GR, GB, FR, TR, SM, SI, SE, RS, RO, PT, PL, NO, NL, FI, ES, EE, DK, DE, CZ, CY, CH, BG, BE, AT, AL | 12.10.2022 | Request for further processing filed | 12.10.2022 | Full payment received (date of receipt of payment) Request granted | 21.10.2022 | Decision despatched | The application is deemed to be withdrawn due to non-payment of the examination fee | 12.10.2022 | Request for further processing filed | 12.10.2022 | Full payment received (date of receipt of payment) Request granted | 21.10.2022 | Decision despatched | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 12.10.2022 | Request for further processing filed | 12.10.2022 | Full payment received (date of receipt of payment) Request granted | 21.10.2022 | Decision despatched | Fees paid | Renewal fee | 10.06.2021 | Renewal fee patent year 03 | 10.06.2021 | Renewal fee patent year 04 | 10.06.2021 | Renewal fee patent year 05 | 10.06.2021 | Renewal fee patent year 06 | 10.06.2021 | Renewal fee patent year 07 | 27.05.2022 | Renewal fee patent year 08 | 30.05.2023 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XD]WO2008058261 (NEUROCRINE BIOSCIENCES INC [US], et al); | [AD]WO2011019956 (BIOVAIL LAB INTERNAT BARBADOS S R L [BB], et al); | [A]US2011053866 (DUFFIELD ANDREW JOHN [GB], et al); | [A]WO2011153157 (AUSPEX PHARMACEUTICAL INC [US], et al); | [AD]WO2014047167 (AUSPEX PHARMACEUTICALS INC [US], et al); | [E]WO2015120317 (NEUROCRINE BIOSCIENCES INC [US]); | by applicant | WO2010018408 | WO2011019956 | US8039627 | US8524733 | WO2014047167 |